683 Capital Management, LLC Affimed N.V. Transaction History

683 Capital Management, LLC

$1.1 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.32 - $0.62 $392,000 - $759,500	-1,225,000 Reduced 14.89%	7,000,000 $4.34 Million
Q3 2023 Nov 14, 2023	SELL	$0.46 - $0.65 $356,500 - $503,750	-775,000 Reduced 8.61%	8,225,000 $3.95 Million
Q4 2022 Feb 14, 2023	BUY	$1.1 - $2.45 $715,000 - $1.59 Million	650,000 Added 7.78%	9,000,000 $11.2 Million
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $1.34 Million - $2.27 Million	685,000 Added 8.94%	8,350,000 $17.2 Million
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $3.46 Million - $7.41 Million	1,525,000 Added 24.84%	7,665,000 $21.2 Million
Q1 2022 May 16, 2022	BUY	$3.69 - $5.65 $883,537 - $1.35 Million	239,441 Added 4.06%	6,140,000 $26.8 Million
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $1.6 Million - $2.11 Million	298,246 Added 5.32%	5,900,559 $32.6 Million
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $1.87 Million - $2.53 Million	337,313 Added 6.41%	5,602,313 $34.6 Million
Q2 2021 Aug 16, 2021	BUY	$7.78 - $11.4 $1.17 Million - $1.71 Million	150,288 Added 2.94%	5,265,000 $44.8 Million
Q1 2021 May 17, 2021	BUY	$5.12 - $8.48 $4.22 Million - $7 Million	825,000 Added 19.23%	5,114,712 $40.5 Million
Q4 2020 Feb 16, 2021	BUY	$3.16 - $7.03 $2.02 Million - $4.5 Million	639,712 Added 17.53%	4,289,712 $25 Million
Q2 2020 Aug 14, 2020	BUY	$1.58 - $4.63 $3.4 Million - $9.95 Million	2,150,000 Added 143.33%	3,650,000 $16.8 Million
Q1 2020 May 15, 2020	BUY	$1.44 - $3.02 $1.55 Million - $3.25 Million	1,075,000 Added 252.94%	1,500,000 $2.37 Million
Q3 2019 Nov 14, 2019	BUY	$2.67 - $3.65 $600,750 - $821,250	225,000 Added 112.5%	425,000 $1.25 Million
Q2 2019 Aug 14, 2019	BUY	$2.6 - $4.21 $520,000 - $842,000	200,000 New	200,000 $575,000

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on 683 Capital Management, LLC with notifications on news.

Account